within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX09_Thymopentin;

model Thymopentin
  extends Pharmacolibrary.Drugs.ATC.L.L03AX09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L03AX09</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Thymopentin is a synthetic pentapeptide corresponding to a sequence of the thymopoietin hormone, predominantly explored for its immunostimulatory activity. It was researched for use in various immunodeficiency states, autoimmune diseases, and as an immunomodulator, including in certain cancers and infections. Thymopentin is not a currently approved drug in most regions and is of mainly historical or investigational interest today.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters in adult humans based on published summaries and peptide characteristics due to the absence of detailed human PK models or compartmental analyses for thymopentin.</p><h4>References</h4><ol><li><p>Shi, M, et al., &amp; Fawcett, JP (2015). Determination of thymopentin in beagle dog blood by liquid chromatography with tandem mass spectrometry and its application to a preclinical pharmacokinetic study. <i>Journal of separation science</i> 38(8) 1351–1357. DOI:<a href=\"https://doi.org/10.1002/jssc.201401198\">10.1002/jssc.201401198</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25631297/\">https://pubmed.ncbi.nlm.nih.gov/25631297</a></p></li><li><p>Zuo, J, et al., &amp; Zhang, Z (2012). Multivesicular liposomes for the sustained release of thymopentin: stability, pharmacokinetics and pharmacodynamics. <i>Die Pharmazie</i> 67(6) 507–512. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22822538/\">https://pubmed.ncbi.nlm.nih.gov/22822538</a></p></li><li><p>He, W, et al., &amp; Zhang, ZR (2008). Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin. <i>Journal of pharmaceutical sciences</i> 97(6) 2250–2259. DOI:<a href=\"https://doi.org/10.1002/jps.21148\">10.1002/jps.21148</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17853430/\">https://pubmed.ncbi.nlm.nih.gov/17853430</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Thymopentin;
